SenesTech公司(纳斯达克股票代码:SNES)公布其2024财年第一季度收入大幅增长，增长78%，达到415,000美元。这一增长在很大程度上归功于他们的新产品Evolve的成功推出，该产品贡献了超过一半的季度收入。尽管营收有所增长，但该公司仍面临180万美元的净亏损。然而，SenesTech对其未来前景表示乐观，包括潜在的正运营现金流和运营费用的减少。

　　SenesTech公司在2024年第一季度的收入增长了78%，达到415,000美元。

　　新的软诱饵产品Evolve是一个主要的收入驱动因素，占该季度销售额的50%以上。

　　该公司完成了一项功效研究，表明使用其产品的啮齿动物数量减少了61%。

　　SenesTech正在通过六渠道战略扩大其分销，并预计未来将通过新产品推出和市场扩张实现增长。

　　该季度净亏损为180万美元，与去年相比有所改善，该公司的目标是在2024年实现正现金流并减少开支。

　　SenesTech对此持乐观态度关于进化鼠标的引入及其对销售的潜在影响。

　　该公司正在努力扩大其制造能力，以满足对Evolve的需求。

　　SenesTech预计，剩余的认股权证将在未来几个季度提供现金来源。

　　该公司报告本季度净亏损180万美元。

　　供应链中的一个问题导致使用成本更高的原料，影响了销售成本。

　　SenesTech已经解决了供应链问题，预计未来毛利率将达到60%或更高。

　　与2023年第一季度相比，运营费用下降了8%。

　　该公司实现了历史上最小的季度调整后EBITDA亏损。

　　尽管收入有所增长，但该公司尚未实现盈利。

　　Tom Chesterman讨论了公司的财务状况，强调了Evolve的成功以及六渠道分销策略的效率。

　　该公司预计，通过亚马逊(纳斯达克股票代码:AMZN)的销售将补充而不是蚕食其自己网站的销售。

　　SenesTech正在与大型害虫公司洽谈控制公司确保供应协议作为进化演示说明了其有效性。

　　SenesTech Inc.制定了明确的增长和成本管理战略，重点是扩大其产品供应和分销渠道。在新产品Evolve的成功和战略合作伙伴关系的支持下，该公司对未来财务表现的信心表明，未来几个月前景乐观。然而，盈利之路仍然是SenesTech面临的一个关键挑战，因为它正在努力将其运营成功转化为积极的底线。

　　SenesTech公司(纳斯达克股票代码:SNES)在其新产品Evolve的成功推出的推动下，在2024年第一季度实现了可观的收入增长。虽然该公司对其未来持乐观态度，但重要的是要考虑可能影响投资者观点的各种财务指标和见解。

　　InvestingPro数据显示，SenesTech的市值为349万美元，截至2023年第四季度，过去12个月的收入增长率为17.08%。这与该公司报告的2024年第一季度收入激增相符。尽管如此，该公司的市盈率仍为-0.45，这反映出它在实现盈利方面面临的挑战。此外，同期的毛利率为45.18%，这是公司有效管理成本能力的一个积极信号。

　　InvestingPro的一个提示强调，分析师预计今年的销售将会增长，这可能意味着Evolve产品发布的势头可能会持续下去。然而，值得注意的是，SenesTech正在迅速烧钱，这是投资者关注的一个关键因素，尤其是考虑到该公司本季度的净亏损。

　　想要了解更全面的SenesTech财务状况和未来前景分析的投资者可以在http://k1.fpubli.cc/file/upload/202405/12/pxrx0djkznw上找到更多的InvestingPro提示。还有12条建议可以提供更深入的见解，包括公司的现金状况、估值倍数和不同时间段内的股票表现。

　　对于那些有兴趣获得这些见解的人来说，使用优惠券代码PRONEWS24可以获得每年或两年一次的Pro和Pro+订阅额外10%的折扣，这对于做出明智的投资决策来说是非常宝贵的。

　　接线员:您好，欢迎您到SenesTech公司。报告2024财年第一季度财务业绩电话会议。所有参与者将处于仅听模式。【操作说明】今天的演示结束后，将有机会提问。[操作说明]请注意此事件正在被记录。现在我想把会议交给莱瑟姆合伙人公司的罗伯特·布鲁姆。请继续。

　　罗伯特?布鲁姆:好吧。非常感谢你，查德，感谢大家参加今天的电话会议。正如运营商SenesTech在截至2024年3月31日的2024年第一季度财务业绩中所示。今天与我们通话的是公司首席执行官Joel Fruendt先生;Tom Chesterman先生，公司首席财务官。在结束今天的发言稿后，我们将开始提问环节。[操作说明]在我们开始准备发言之前，我们提交以下声明以供记录。SenesTech管理团队在本次电话会议期间所作的陈述可能包含《1933年证券法》(修订版)第27A条和《1934年证券法》(修订版)第21E条所指的前瞻性陈述，此类前瞻性陈述是根据《1995年私人证券诉讼改革法案》的安全港条款作出的。前瞻性陈述描述未来的期望、计划、结果或策略，通常在陈述前加上可能、未来、计划或计划、将或应该、预期、预期、草案、最终或预计等词语。请听众注意，此类陈述可能受到多种风险和不确定性的影响，这些风险和不确定性可能导致未来的情况、事件或结果与前瞻性陈述中的预测产生重大差异，包括由于公司向证券交易委员会提交的文件中确定的各种因素和其他风险，实际结果可能与前瞻性陈述中的预测产生重大差异的风险。本电话会议中包含的所有前瞻性陈述仅以其发表之日为基准，并基于管理层截至该日期的假设和估计。公司不承担因收到新信息、未来事件发生或其他原因而公开更新任何前瞻性陈述的任何义务。说到这里，让我把电话交给首席执行官Joel Fruendt;SenesTech。乔尔，请继续。

　　Joel Fruendt: Thank you, Robert. Good afternoon, everyone. Thank you for joining us today for our Q1 conference call. I certainly couldn't be more pleased to be speaking with you today, given all the positive developments going on with the company. So let me jump right into it. During the first quarter, we reported record revenue of $415,000, an increase of 78% compared to the first quarter of last year. This was also a 41% increase sequentially from the fourth quarter of 2023. Key driver has been the introduction of Evolve, our all-new soft bait product launched in January of this year, which has quickly become the company's biggest selling product contributing more than 50% of first quarter revenue. As a reminder, Evolve is an EPA designated minimum risk product and brings three key benefits to the marketplace: one, a shelf life of one year plus, so it is an excellent rodent control product for distribution. Two, it is delivered in a soft bait form factor, so it is familiar and easy to use in the field and three, it is economical and is offered at a competitive price to traditional rodenticides. I will come back to this more in a moment. One point to make regarding the revenues. This outstanding growth reflected regulatory approval of Evolve in only 30 states. There are several states including high potential states such as Florida that required an efficacy study before approval. That efficacy study is now complete which bodes well for acceptance by the remaining states and further accelerated growth in Q2. Speaking of the efficacy study, we finished up our study at the University of Arizona last month and the results were positive, as expected and predicted from the literature available on the active ingredient and from our experience with ContraPest. The study results ////confirm/i/i/i/ied, a 61% reduction in litter size through only one breeding cycle. This indicates an 85% reduction in population over six months, compared to leaving the population untreated and 90% plus after one year. We will now start some longer term field trials at customer locations and we fully expect the efficacy to increase significantly over multiple litters with increased consumption and with real-world conditions. This is actually a little better than our first short-term study with ContraPest, which then went on to prove out over 90% efficacy in longer-term field studies. We expect Evolve will prove to be the product of choice for rodent population control. With this published report, we now have the data requested by certain state and international regulators, increasing the conversion potential for the rest of this year. Another key highlight was our introduction of Evolve Mouse this month. This soft bait product utilizes the same revolutionary breakthrough fertility solution anti-valve only to control mouse infestations, effectively doubling our addressable market opportunity. One of our lead distributors and online retailers, DIY Pest Control has already committed to a sizable preorder and will immediately add Evolve Mouse to their website offerings. Product shipments began last week and we expect Evolve Mouse to be a key driver to growth throughout the rest of the year. This effectively doubles our addressable market opportunity. It has been estimated that US rodent and pest management product sales over half of which target mouse infestations are more than $1 billion annually and are growing. At the same time, regulators in California and other areas are putting more restrictions on the application of commonly used poisons, leading consumers and pest managers to seek new methods for control and ease of purchase options, providing us with an enhanced opportunity going forward. Evolve has proven to be a very versatile product that is perfect for many distribution channels that focus on our target markets. To keep focus on each of these areas, we have developed our sixth channel strategy for distribution. Our six channels are e-commerce, international, agribusiness, pest management, industrial and retail. We have strategies designed for each channel, and I will briefly comment on progress in each channel. In the e-commerce space, we have expanded the offerings on our own site significantly. We are also proud to announce the launch of a dedicated Amazon store, which we have launched this week. This was really made possible by the introduction of Evolve and by the expansion of our packaging from the initial six-pound and 12-pound pail sizes that are so popular with the professional market to now include 1.5 pound and three-pound pouches that are more convenient for the consumer market, as well as being more earth-friendly with their packaging. The international channel has seen substantial interest and activity. Since Evolve's launch, we have signed six key international exclusive distribution agreements from Hong Kong to Australia to the UAE. Each of the agreements requires an initial order of a full pallet minimum to around $10,000 and the annual sales minimum started $100,000 for exclusive distribution rights and grow over time. In our agribusiness channel, we announced a new agreement with Wilco Distributing who placed a multi-pallet stocking order, addressing some very lucrative open field agriculture opportunities. This followed agreements with Poppe Enterprises for the grain management area and Agricom for the ag production and protein production facilities management. In the pest management channel, we have signed agreements and have initial stocking orders from Tusera [ph] in their 77 locations and DIY Pest Control to satisfy demand from their significant pest control customer base. Our commitment by our field staff to the pest management market, pest control operators and government agencies is creating a pull-through effect where local availability in distributors' warehouses is a key factor in driving revenue growth. We have identified a significant opportunity in the industrial channel and are finalizing agreements for an industrial rep agency with 28 outside sales reps to assist us in giving Evolve stock at substantial industrial distributors such as Grainger and Fastenal (NASDAQ:FAST). This will be our channel to reach the Facilities Management and Food Safety Markets as well. We expect this agreement to be completed soon. And as we talked about during our year-end call, we are excited about the opportunities in the retail channel. Since we received approval, as a vendor for a national hardware retailer which consists of over 4,500 locations, we have now completed the process of getting setup in their system with our Evolve products. We have also signed on to attend their August market days, to display our products for purchase by location managers and owners. To enhance our presence and fully address that network, and other similar retailers, we have signed a rep agency with over 30 field reps, to represent us with these major national and regional retailers in home supply, hardware and Ag retail locations. This will be a key sales driver for us in 2024. Using distribution channels to leverage and extend our sales reach is a key initiative for the year, and we are off to a great start. You can expect further news in the coming months, as we further penetrate the Retail and Warehouse club networks. Finally, and as I assume most of you saw in the news, the New York City Council introduced a proposal for deployment of EPA-approved, rat birth control to address rodent infestations. The NASDAQ is the only manufacturer of commercially available EPA-registered rat birth control which we believe, bodes well for our opportunity. While New York City is not at all the urban market for us, it is a highly visible one and one that we will pursue after trying home remedies, dry ice, drowning buckets and other improvement tools it is good to see that the city is finally looking at tested and proven techniques. To wrap, I firmly believe, the tide has shifted for SenesTech. We have the right product solutions to address one of the world's most challenging problems, rodent control, through a completely different way than has ever been done before, by addressing the root cause of the problem Reproduction, and how to proactively control that Reproduction. Our product lines ContraPest and Evolve address the fundamental issue of rodent overpopulation by proactively controlling the population, rather than trying to keep up with the growing numbers of an infestation with poisons or traps alone. Remember, two rats can turn into 15,000 in one year alone. You just can't kill them fast enough. In fact during this call there will be tens of thousand rats, across the globe. Pest management, professionals and homeowners are seeking alternatives to poisons, as poisons are highly regulated and are tricky to use less poisons are less than 40% effective. Clearly the development evolve is a game changer for them and for us as well. To give you more detail on that and on the financials, let me turn the call over to Tom. Tom?

　　汤姆·切斯特曼:谢谢，乔尔。提醒我们的投资者，新闻稿可在我们网站的投资者关系部分找到，这将是这次演讲的录音。此外，我们希望在今天晚些时候提交10-Q文件，所以我现在只谈一些重点。第一季度的收入为415,000美元，比2023年第一季度的233,000美元增长了78%。正如Joel所提到的，主要驱动力是《Evolve》，它占了我们第一季度销售额的50%以上。从我们的垂直分销来看，我们看到了销售额和害虫管理专业人员以及商业客户的显著增长。我在上个季度提到过这一点，但我要再次提醒大家，由于《Evolve》的成功，我们不得不扩大我们的制造能力。今天，我们每天的产能约为1000磅，很快将达到2000磅，并有明确的路径达到每天4000磅，足以满足当前的需求。到目前为止，Evolve分为6磅和12磅两种，最适合专业市场;1.5磅和3磅两种，最适合消费者市场，我们从3月份开始发货。考虑到原材料和成品的增加，我们扩大了凤凰城的仓库空间。由于供应链问题，2024年第一季度的销售成本受到我们新产品中关键成分成本上升的影响。我们尽快纠正了这个问题，但在生产的头几个月，我们被迫使用了成本更高的原料。我们在第一季度末完成了转型。给你举个例子，如果我们在第一季度使用预定的原材料，就像我们现在这样，我们的毛利润将是52%。作为即时确认，我们4月份的初步毛利率为58%。展望未来，我们现在有一个可靠的供应链流程，这将确保这种情况不会再次发生。最终，尽管contr佩斯的毛利率约为50%，但Evolve的毛利率有可能达到60%甚至更多。本季度的运营费用为200万美元，与2023年同期的210万美元相比下降了8%。我们在经营结构上做了许多改变。该公司仍致力于提高运营效率，目标是到2024年每年再减少100万美元的运营费用。本季度净亏损为180万美元，而2023年第一季度净亏损为200万美元，减少了20万美元。2024年第一季度调整后EBITDA亏损为170万美元，而2023年第一季度为180万美元，这是衡量经营业绩的非gaap指标。季度调整后的EBITDA亏损是公司历史上最小的，因为我们努力实现实现正经营现金流的目标。本季度末现金为360万美元。在上次融资后，我们有大约310万份短期认股权证尚未发行，我们乐观地认为，随着我们继续执行我们的商业计划，剩余的认股权证将成为未来几个季度的现金来源。说到这里，查德，现在请大家提问。

　　接线员:非常感谢。现在开始我们的问答环节。【操作说明】

　　罗伯特·布鲁姆:查德，这是罗伯特。我先插话看看有没有人打进来通过网站问一些问题。同样，对于任何在网站上收听的人，请随意键入你的问题，通过提示，在网络广播播放器上的问题提示框。乔尔和汤姆，我们有一个问题，关于你们鼠标产品的销售前景，我们对下一季度的预期是什么?

　　乔尔:是的。就像我们的第一款产品一样，有些州会立即接受EPA的最低风险认定，而其他州则会有额外的问题或要求。这可能比我们的第一个产品卖得更快。但我们应该假设《Evolve》鼠标将逐渐获得州政府的批准，我们将在一年内将《Evolve》的销售额提升至15%至25%。

　　罗伯特·布鲁姆:好的。太好了。[操作员说明]看来我们还有一个问题。你是否期望亚马逊商店会蚕食你自己网站的销售额?或者你认为是不同的客户?

　　Joel Fruendt:我们的网站上有一些很棒的客户，我相信他们会继续在那里购物。亚马逊是一个强大的渠道。可能会有很多客户喜欢它，但也有很多客户更喜欢直接与公司打交道。所以在任何情况下，无论他们是想在我们的网站上购买还是在亚马逊上购买或者定价策略都是中性的。所以我们相信亚马逊渠道的力量将会越来越强大。

　　罗伯特?布鲁姆:好吧。太棒了。看起来我们还有一个问题。怎样才能与主要的害虫防治公司达成分销协议?

　　乔尔·弗伦特:所以我们与主要的害虫控制公司保持联系，我们确实有一些他们的地方正在使用它。因此，我们认为，随着我们与Evolve公司的进一步合作，在这一领域已经得到了证明，害虫防治公司，以及为害虫防治提供服务的分销公司，将愿意考虑某种形式的供应协议。我们对此很有信心。

　　罗伯特·布鲁姆:好的。太好了。看来我们没有其他问题了。乔尔，我把它交给你来做结束语。

　　乔尔:谢谢你，罗伯特。感谢大家今天的光临。对于SenesTech来说，今年将是杰出的一年，我期待着在未来的几个月里与大家分享我们的成功。谢谢你！

　　接线员:会议到此结束。感谢您参加今天的演讲。您现在可以断开连接。

　　本文是在人工智能的支持下生成的，并由编辑审阅。欲了解更多信息，请参阅我们的T&C。